Analyst Price Targets — QURE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 9:25 am | — | Barclays | $60.00 | $40.07 | TheFly | uniQure price target lowered to $60 from $65 at Barclays |
| June 29, 2026 9:57 am | — | H.C. Wainwright | $80.00 | $47.51 | TheFly | uniQure price target raised to $80 from $50 at H.C. Wainwright |
| June 25, 2026 10:33 am | Uy Ear | Mizuho Securities | $68.00 | $48.85 | StreetInsider | uniQure BV (QURE) PT Raised to $68 at Mizuho |
| June 18, 2026 11:12 am | — | RBC Capital | $65.00 | $48.16 | TheFly | uniQure price target raised to $65 from $35 at RBC Capital |
| June 18, 2026 11:07 am | — | Barclays | $65.00 | $48.16 | TheFly | uniQure upgraded to Overweight from Equal Weight at Barclays |
| June 18, 2026 10:43 am | Joseph Schwartz | Leerink Partners | $70.00 | $48.16 | StreetInsider | uniQure BV (QURE) PT Raised to $70 at Leerink |
| June 18, 2026 10:20 am | Salveen Richter | Goldman Sachs | $46.00 | $48.16 | TheFly | uniQure price target raised to $46 from $14 at Goldman Sachs |
| June 17, 2026 3:46 pm | — | Cantor Fitzgerald | $61.00 | $47.40 | TheFly | uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news |
| May 6, 2026 2:17 pm | Patrick Trucchio | H.C. Wainwright | $50.00 | $21.64 | TheFly | uniQure price target lowered to $50 from $70 at H.C. Wainwright |
| May 5, 2026 3:37 pm | Paul Matteis | Stifel Nicolaus | $28.00 | $20.78 | TheFly | uniQure price target raised to $28 from $14 at Stifel |
Latest News for QURE
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
On Wednesday, uniQure N.V. (NASDAQ:QURE) submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease.
Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its experimental treatment for Huntington's disease after the FDA reversed its earlier position on the drug, sending the company's shares up 5% in premarket trading.
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the Phase I/II study, in which ifezuntirgene inilparvovec demonstrated a slowing of disease progression ~ LEXINGTON, Mass. and AMSTERDAM, Sept.
uniQure (QURE) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QURE.
U.S. House Trading
No House trades found for QURE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.